ESR1 fusions that contain the first six exons of ESR1 fused in-frame to partner genes are almost exclusively observed in endocrine therapy resistant, metastatic ER+ breast cancer, with the exception of ESR1-e6>NOP2, as described above, likely suggesting a role in driving disease pathogenesis. This evidence concerns the gene ESR1 and breast cancer.